nausea & vomiting due to 'squashed stomach syndrome'
dyspnoea
oesophageal reflux
Treatment options
chemotherapy - intraperitoneal or systemic
paracentesis
diuretics
peritoneovenous shunt
Management
Chemotherapy can be considered if the prognosis warrants, but for most patients, therapy aimed at symptomatic control is appropriate.
Paracentesis is the treatment of choice for rapid symptom control.
Repeated paracentesis as needed is appropriate for most patients with a poor prognosis of <4-6 weeks e.g. gross hepatomegaly or jaundice.
Commence diuretics if prognosis > 4 weeks, paracentesis not accepted or unsuccessful. Leg oedema is an additional indication for using diuretics. See diuretic regime below.
If diuretics unsuccessful, or for persistently recurring ascites, consider a peritoneovenous shunt - can be effective, but shunt obstruction, sepsis and other complications are frequent.[1-3]
Diuretic regime
Spironolactone is the drug of choice for ascites, as increased plasma rennin activity and sodium retention occur in malignant ascites. Doses between 100-400mg o.d. are used. However it takes about 7 days to improve symptoms, and up to 28 days for full effect.[4-7] The addition of furosemide will help achieve a more rapid response until spironolactone works,[7] or may help in cases resistant to spironolactone alone.
Start spironolactone 100mg o.d.
Add furosemide 40mg o.d. if rapid initial result desired, as long as the patient is not dehydrated/hypovolaemic:
aim to withdraw furosemide after a week or so
Increase spironolactone by 100mg increments once or twice weekly to maximum 200mg b.d.
If ascites is resistant to 400mg spironolactone, add furosemide 40mg o.d. increased if necessary to 80mg o.d.
If little or no response to furosemide, change to bumetanide 2mg o.d. or furosemide 100mg/24h by CSCI.[8]
Monitoring
Patients on diuretics should be monitored closely for dehydration (indicated by U&Es, thirst, postural hypotension or confusion). Girth measurements can be used once to twice weekly to monitor the effect of diuretics.
Some drug treatments mentioned in this topic may be outside the drug's product licence. Drugs Information
References
Faught W, Kirkpatrick JR, Krepart GV, et al. Peritoneovenous shunt for palliation of gynecologic malignant ascites. J Am Coll Surg 1995;180(4):472-4 [abstract]
Schumacher DL, Saclarides TJ, Staren ED. Peritoneovenous shunts for palliation of the patient with malignant ascites. (clinical trial) Ann Surg Oncol 1994;1(5):378-81 [abstract]
Söderlund C. Denver peritoneovenous shunting for malignant or cirrhotic ascites. A prospective consecutive series. Scand J Gastroenterol 1986;21(10):1161-72 [abstract]
Greenway B, Johnson PJ, Williams R. Control of malignant ascites with spironolactone. Br J Surg 1982;69(8):441-2 [abstract]
Arroyo V, Ginès P, Planas R. Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt, and large-volume paracentesis. (review) Gastroenterol Clin North Am 1992;21(1):237-56 [abstract]
De Simone GG. Treatment of malignant ascites. Prog Paliat Care 1999;7(1):10-16
Fogel MR, Sawhney VK, Neal EA, et al. Diuresis in the ascitic patient: a randomized controlled trial of three regimens. (clinical trial) J Clin Gastroenterol 1981;3 Suppl 1:73-80 [abstract][full textsubs]
Amiel SA, Blackburn AM, Rubens RD. Intravenous infusion of frusemide as treatment for ascites in malignant disease. Br Med J (Clin Res Ed) 1984;288(6423):1041 [more][FULL TEXTFREE]
Edition/Revision: 1.0
Created 1 Aug 2001
Validated 1 Aug 2001 by Ian Back